Company intelligence / Profile preview

SkinBioTherapeutics

Newcastle upon Tyne, United Kingdomskinbiotherapeutics.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

The company has shown that its SkinBiotix® platform can improve the barrier effect of skin models, protect skin from infection, and repair skin models. Proof of principle studies have demonstrated beneficial attributes applicable to multiple areas of skin health[1][2].

Therapeutic areas: Dermatology
Modalities: Probiotic bacteria lysates
Industry: Biotech

Drug pipeline

1 asset

AxisBiotix-Ps

Unknown

Partnerships

Croda Plc (for development of SkinBiotix as an active ingredient for the skincare/cosmetic industry)[5]

Beyond the preview

Go deeper on SkinBioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SkinBioTherapeutics.

Explore the full profile